Effects of capecitabine (X) on quality of life (QoL) in patients (pts) with metastatic colorectal cancer (MCRC)

Beato, C.; Federico, Miriam Hatsue Honda; Eyll, Brigitte Van; Cabral, S.; Perdicaris, M.; Skare, N.; Lago, S.; Carvalho, Marcelo Prado de; Moura, G. L.; Duarte, R. C.

doi:10.1200/jco.2004.22.90140.8119

Cited by 3 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There have been several reports from a large, ongoing Brazilian study of QoL [56][57][58][59]. Most recently, 611 anthracycline-and/or taxane-resistant patients with metastatic breast cancer received the standard regimen of oral capecitabine and were evaluated at baseline, week 7, week 13, and at end of treatment using the EORTC QLQ and BR-38 questionnaires [56,60,61].…”

Section: Quality Of Lifementioning

confidence: 99%

Capecitabine Monotherapy: Safe and Effective Treatment for Metastatic Breast Cancer

Ershler

2006

The Oncologist

View full text Add to dashboard Cite

After completing this course, the reader will be able to:1. Describe the pharmacology of capecitabine.2. Discuss the use of capecitabine as a single agent and in refractory disease. AbstractOptimal management for metastatic breast cancer frequently involves cytotoxic chemotherapy. Over the years, several complex multidrug regimens have been developed that were based upon a rationale of synergistic antitumor activity and nonoverlapping toxicities. However, recently the clinical value of these complex regimens has been called into question as several drugs used alone (monotherapy) or in sequence (serial single agent) have been shown to be both efficacious and better tolerated. Capecitabine (an orally administered fluoropyrimidine carbamate) is one such agent that has been proven to be effective when used alone for metastatic breast cancer, metastatic colorectal cancer, and adjuvant colon cancer. In this review, published (or reported in abstract form) data examining various aspects of clinical response and tolerability with single-agent capecitabine for (primarily) first-and second-line metastatic breast cancer are examined. For the most part, response rates are comparable with those of the more complex regimens. Dose reductions from the labeled dose of 1,250 mg/m 2 twice daily are relatively common. Toxicities (following dose reductions if needed) are generally manageable, even by more frail patients. Elderly patients are more likely to have impaired renal function or be receiving warfarin treatment, and special attention to these factors is warranted. Nonetheless, the drug administered alone is a reasonable choice when singleagent chemotherapy is entertained as a treatment option for metastatic breast cancer, including in the first-line setting. The Oncologist 2006;11:325-335

show abstract